<p>马萨诸塞州剑桥、荷兰鹿特丹和中国上海，/PRNewswire/ -- Harbour BioMed（香港交易所代码：02142）是一家全球生物制药公司，致力于在免疫学和肿瘤学领域发现和开发新型抗体治疗药物。今天，该公司宣布通过其全资子公司行使其认股权证，以收购 Spruce Biosciences, Inc.（纳斯达克代码：SPRB）（&#34;Spruce&#34;）的普通股。在此次交易后，Harbour BioMed 持有 Spruce 约 3.8% 的总流通股和约 3.1% 的完全稀释股份 [1]。</p>
<p>该认股权证最初是发放给 Harbour BioMed 的子公司和 HBM Alpha Therapeutics（&#34;HBMAT&#34;）的其他少数股东，HBM Alpha Therapeutics 是一家由 Harbour BioMed 孵化的创新生物技术公司，涉及与 Spruce 之间的许可和合作协议。该合作旨在推进 SPR202（前称为 Harbour BioMed 的 HBM9013）的开发，这是一种针对各种疾病的强效选择性抗促肾上腺皮质激素释放激素单克隆抗体，包括先天性肾上腺增生。</p>
<p>Harbour BioMed 的创始人、董事长兼首席执行官王景松博士表示：&#34;此次认股权证的行使标志着我们与 Spruce Biosciences 关系的重要里程碑。这使我们超越了传统的许可方 - 被许可方关系，建立了真正对齐的战略合作伙伴关系，强化了我们共同致力于加速全球患者转化疗法开发的承诺。&#34;</p>
<p>[1] 根据截至 2025 年 9 月 30 日的 Spruce 总流通股和完全稀释股份计算。</p>
<p><strong>关于 Harbour BioMed</strong></p>
<p>Harbour BioMed（香港交易所代码：02142）是一家全球生物制药公司，致力于在免疫学和肿瘤学领域发现和开发新型抗体治疗药物。该公司通过内部研发能力、全球战略合作进行共同发现和共同开发，以及选择性收购，建立了强大且差异化的产品管线。</p>
<p>Harbour BioMed 的专有抗体技术平台 Harbour Mice®能够生成完全人源的单克隆抗体，采用传统的两重重链和两重轻链（H2L2）格式以及仅重链（HCAb）格式。在 HCAb 抗体的基础上，HCAb 基础的免疫细胞激活剂（HBICE®）双特异性抗体技术能够实现传统组合疗法无法达到的肿瘤杀伤效果。此外，HCAb 基础的双特异性免疫细胞拮抗剂（HBICATM）技术推动了针对免疫和炎症疾病的创新生物制剂的开发。通过将 Harbour Mice®、HBICE®和 HBICATM 与单一 B 细胞克隆平台整合，Harbour BioMed 建立了一个高效且独特的抗体发现引擎，用于开发下一代治疗抗体。有关更多信息，请访问 www.harbourbiomed.com。</p>
<p>来源：Harbour BioMed</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9Q042NTY2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTAyUFJfTkVXU19VU1BSX19fX19DTjY1NjY2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9Q042NTY2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTAyUFJfTkVXU19VU1BSX19fX19DTjY1NjY2"/></p>

SPRBD

SPRB

<p>Harbour BioMed 已经收购了 Spruce Biosciences 的普通股，将其持股比例提高至大约 3.8% 的总流通股。这次通过行使认股权证进行的收购，标志着他们在战略合作伙伴关系中迈出了重要一步，旨在推动 SPR202 的开发，这是一种用于多种疾病的单克隆抗体。王景松博士强调了这一里程碑在加强他们合作关系、加速为患者提供变革性疗法方面的重要性</p>

<p>CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) (&#34;Spruce&#34;). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].</p>
<div class="lb-trans"><p>马萨诸塞州剑桥、荷兰鹿特丹和中国上海，/PRNewswire/ -- Harbour BioMed（香港交易所代码：02142）是一家全球生物制药公司，致力于在免疫学和肿瘤学领域发现和开发新型抗体治疗药物。今天，该公司宣布通过其全资子公司行使其认股权证，以收购 Spruce Biosciences, Inc.（纳斯达克代码：SPRB）（&#34;Spruce&#34;）的普通股。在此次交易后，Harbour BioMed 持有 Spruce 约 3.8% 的总流通股和约 3.1% 的完全稀释股份 [1]。</p>
</div><p>The warrant was originally issued to Harbour BioMed's subsidiary and other minority shareholders of HBM Alpha Therapeutics (&#34;HBMAT&#34;), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia.</p>
<div class="lb-trans"><p>该认股权证最初是发放给 Harbour BioMed 的子公司和 HBM Alpha Therapeutics（&#34;HBMAT&#34;）的其他少数股东，HBM Alpha Therapeutics 是一家由 Harbour BioMed 孵化的创新生物技术公司，涉及与 Spruce 之间的许可和合作协议。该合作旨在推进 SPR202（前称为 Harbour BioMed 的 HBM9013）的开发，这是一种针对各种疾病的强效选择性抗促肾上腺皮质激素释放激素单克隆抗体，包括先天性肾上腺增生。</p>
</div><p>Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, stated: &#34;This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide.&#34;</p>
<div class="lb-trans"><p>Harbour BioMed 的创始人、董事长兼首席执行官王景松博士表示：&#34;此次认股权证的行使标志着我们与 Spruce Biosciences 关系的重要里程碑。这使我们超越了传统的许可方 - 被许可方关系，建立了真正对齐的战略合作伙伴关系，强化了我们共同致力于加速全球患者转化疗法开发的承诺。&#34;</p>
</div><p>[1] Calculated based on the total outstanding shares and fully diluted shares of Spruce as of September 30, 2025.</p>
<div class="lb-trans"><p>[1] 根据截至 2025 年 9 月 30 日的 Spruce 总流通股和完全稀释股份计算。</p>
</div><p><strong>About Harbour BioMed</strong></p>
<div class="lb-trans"><p><strong>关于 Harbour BioMed</strong></p>
</div><p>Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&amp;D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.</p>
<div class="lb-trans"><p>Harbour BioMed（香港交易所代码：02142）是一家全球生物制药公司，致力于在免疫学和肿瘤学领域发现和开发新型抗体治疗药物。该公司通过内部研发能力、全球战略合作进行共同发现和共同开发，以及选择性收购，建立了强大且差异化的产品管线。</p>
</div><p>Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.</p>
<div class="lb-trans"><p>Harbour BioMed 的专有抗体技术平台 Harbour Mice®能够生成完全人源的单克隆抗体，采用传统的两重重链和两重轻链（H2L2）格式以及仅重链（HCAb）格式。在 HCAb 抗体的基础上，HCAb 基础的免疫细胞激活剂（HBICE®）双特异性抗体技术能够实现传统组合疗法无法达到的肿瘤杀伤效果。此外，HCAb 基础的双特异性免疫细胞拮抗剂（HBICATM）技术推动了针对免疫和炎症疾病的创新生物制剂的开发。通过将 Harbour Mice®、HBICE®和 HBICATM 与单一 B 细胞克隆平台整合，Harbour BioMed 建立了一个高效且独特的抗体发现引擎，用于开发下一代治疗抗体。有关更多信息，请访问 www.harbourbiomed.com。</p>
</div><p>SOURCE Harbour BioMed</p>
<div class="lb-trans"><p>来源：Harbour BioMed</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE4Jk5ld3NJdGVtSWQ9Q042NTY2NiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTgxOTAyUFJfTkVXU19VU1BSX19fX19DTjY1NjY2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN65666&amp;Transmission_Id=202601181902PR_NEWS_USPR_____CN65666&amp;DateId=20260118"/></p>

Harbour BioMed 收购 Spruce Biosciences 的普通股，深化战略合作